Newron Pharmaceuticals S.p.A. (FRA:NP5)

Market Cap	174.79M
Revenue (ttm)	51.39M
Net Income (ttm)	15.84M
Shares Out	n/a
EPS (ttm)	0.77
PE Ratio	11.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,960
Average Volume	4,084
Open	9.02
Previous Close	8.62
Day's Range	8.56 - 9.02
52-Week Range	6.03 - 11.90
Beta	n/a
RSI	57.01
Earnings Date	Sep 16, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 22
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NP5